Vascular protection with dipeptidyl peptidase-IV inhibitors in diabetes: experimental and clinical therapeutics.

about

Sitagliptin Accelerates Endothelial Regeneration after Vascular Injury Independent from GLP1 Receptor Signaling.

P2860

Q52807797-8017E6BB-ED13-4569-8CCC-B4C4077553FE

P2860

Vascular protection with dipeptidyl peptidase-IV inhibitors in diabetes: experimental and clinical therapeutics.

Item

http://www.wikidata.org/entity/Q38371242

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Vascular protection with dipep ...... tal and clinical therapeutics.

@en

type

Item

label

Vascular protection with dipep ...... tal and clinical therapeutics.

@en

prefLabel

Vascular protection with dipep ...... tal and clinical therapeutics.

@en

P1476

Vascular protection with dipep ...... tal and clinical therapeutics.

@en

P2093

Dianne W May

http://www.w3.org/2001/XMLSchema#string

Heba A Ahmed

http://www.w3.org/2001/XMLSchema#string

Lakshman Segar

http://www.w3.org/2001/XMLSchema#string

Susan C Fagan

http://www.w3.org/2001/XMLSchema#string

P2860

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants

A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

Standards of medical care in diabetes--2014

Central neuropeptide Y signaling ameliorates N(omega)-nitro-L-arginine methyl ester hypertension in the rat through a Y1 receptor mechanism

Inflammation, atherosclerosis, and coronary artery disease

The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.

Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat)

P304

277-297

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PHAR.1547

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-03-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25754657

http://www.w3.org/2001/XMLSchema#string

Vascular protection with dipeptidyl peptidase-IV inhibitors in diabetes: experimental and clinical therapeutics.

about

P2860

P2860

Vascular protection with dipeptidyl peptidase-IV inhibitors in diabetes: experimental and clinical therapeutics.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698